Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
Explore More Articles
Laser scleral microporation helps turn back the clock for presbyopic eyes
VIENNA — In this Healio Video Perspective from the ESCRS meeting, Robert Ang, MD, shares his results with laser scleral microporation for the treatment of presbyopia. He explains the rationale of laser scleral microporation (Ace Vision Group), how it is performed, and the advantages of a treatment that does not interfere with the visual axis and allows the …
read moreA New Paradigm Shift: Parts 1 and 2 (Pages 25-31)
DUE TO THE AGING OF THE population, most of our population will spend roughly half of their lives as presby-opes. The etiology of presby-opia has been poorly understood, and treatment options have failed to address the true issues with the disease, creating compro mises in vision that patients are eager to find a solution for, …
read moreDr. Robert Ang in CRST
What other future treatments have promise? Laser scleral microporation is under investigation as a laser treatment for patients with emmetropic presbyopia. Four quadrants of the sclera are treated with an Er:YAG laser to uncrosslink the sclera and rejuvenate the accommodative mechanism (see video demonstration below). Treatment does not appear to affect the visual axis or …
read more